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Co-expression of POU4F2/Brn-3b with p53 may be
important for controlling expression of pro-apoptotic
genes in cardiomyocytes following ischaemic/hypoxic
insults
V Budhram-Mahadeo*,1, R Fujita1, S Bitsi1, P Sicard2 and R Heads2
Cardiomyocyte death following ischaemic/hypoxic injury causes irreversible damage to cardiac function and contributes to
chronic diseases such as heart failure. Understanding the mechanisms associated with myocyte loss under these conditions can
help to identify strategies to minimise/abrogate such detrimental effects. The p53 protein can induce apoptosis or cell cycle arrest,
but effects on cell fate depend on interactions with other regulators such as POU4F2/Brn-3b (Brn-3b), which co-operates with p53
to increase the expression of pro-apoptotic genes. In contrast, the related POU4F1/Brn-3a (Brn-3a) blocks p53-mediated apoptosis
but co-operates with p53 to enhance cell cycle arrest. In this study, we showed that permanent coronary artery ligation in mouse
hearts, which induced apoptotic markers, activated caspase-3 and -8 and necroptosis markers; RIP-1 and -3 also increased Brn-3b
and Brn-3a expression. However, Brn-3a was only detected in uninjured myocardium but not at the site of injury, whereas Brn-3b
showed generalised increase, including within the infarct zone. Conversely, p53 was detected in the infarct zone and in some cells
adjacent to the site of injury but not in uninjured myocardium. Co-localisation studies showed Brn-3a co-expression with p53 in
cardiomyocytes adjacent to the infarct zone, whereas Brn-3b was co-localised with p53 in the infarct zone only. Increased Brn-3b
and p53 correlated with elevated expression of pro-apoptotic target genes, Bax, Noxa and PUMA, whereas cleaved caspase-3
confirmed the presence of apoptotic cells within this region of the injured heart. Similarly, simulated ischaemia/reoxygenation
(sI/R) injury in neonatal rat ventricular cardiomyocytes (NRVM) and heart derived H9c2 myoblasts increased Brn-3b, p53 as well as
apoptotic genes, and this was associated with enhanced apoptosis. Furthermore, targeted reduction of Brn-3b using shRNA
caused reduction in pro-apoptotic Bax and Noxa proteins, even though p53 expression remained intact, suggesting that Brn-3b is
important for controlling the fate of the myocardium in the injured heart.
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During myocardial infarction (MI), prolonged ischaemia and/or
hypoxia can cause the death of cardiomyocytes that adversely
affect cardiac function.1,2 Modes of cell death implicated in
such cell loss include necrosis, programmed necrosis
(necroptosis), apoptosis and autophagy2,3 and these vary in
relation to the site of injury. For example, necrotic cells are
seen primarily within the central ischaemic zone, whereas
apoptotic cardiomyocytes are detected in the infarct zone and
‘border zone’ myocardium, adjacent to the site of injury.
Interestingly, apoptotic cells are detectable within 2 h after
injury, induced by coronary artery ligation4–7 but are also
implicated in longer-term cardiomyocyte loss that contributes
to heart failure.7
However, although necrotic cell death is associated with
changes such as loss of inner mitochondrial membrane
potential, MPTP opening and inflammation, programmed cell
death such as necroptosis and apoptosis require dynamic
changes in gene expression. Thus, necroptosis is accompa-
nied by activation of receptor-interacting proteins, RIP1/38,9
whereas apoptosis is characterised by increased expression
of pro-apoptotic proteins and activation of caspases.10–12
Therefore, DNA-binding transcription factors (TFs) that acti-
vate or repress the transcription of genes that encode such
proteins will be important for regulating these processes.13
However, the effects of TFs are modulated by interaction with
other proteins in the transcriptional complex.13,14
The Brn-3b and Brn-3a are related, but distinct proteins,
encoded by different genes, that belong to the POU (Pit-Oct-
Unc) family of TFs.15 These proteins exist as two isoforms that
differ in size because of the presence of an additional N0
terminal domain in the longer proteins, for example, Brn-3b(l),
that is not found in the shorter Brn-3b(s),16,17 but the functions
of these distinct isoforms are still to be elucidated. Brn-3b
share high homology (490%) with Brn-3a in the DNA-binding
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POU domain,18 which means that these TFs bind to similar
DNA sites in target gene promoters. However, limited
sequence similarity outside of the POU domain15 causes
distinct effects on gene expression and cell fate, which is also
affected by the interaction with other cellular regulators. For
example, Brn-3b drives growth and proliferation in some cells
by enhancing the expression of cell cycle proteins such as
cyclin D1 and CDK4.19,20 Accordingly, elevated Brn-3b in solid
tumours, such as childhood neuroblastomas and breast
cancers, correlates with increased cyclin D1 levels.17,21–23
However, if growth-promoting Brn-3b is co-expressed with
p53, which inhibits cell growth, such conflicting signals drive
apoptosis and under such conditions, Brn-3b interacts and co-
operates with p53 to increase transcription of pro-apoptotic
Bax, thereby increasing cell death.24
In contrast, the related Brn-3a supports survival and
differentiation in neuronal cells by transactivating genes
encoding anti-apoptotic proteins (e.g., Bcl-2 and Bcl-XL)
and neuronal proteins (e.g., neurofilament; α-internexin;
SNAP25).25–27 However, Brn-3a also interacts with p53 but
blocks the transactivation of pro-apoptotic genes whilst co-
operating with p53 to enhance the expression of the cell cycle
inhibitor, p21cip1/waf1.28–30 As Brn-3b and Brn-3a have
antagonistic effects on survival when co-expressed with p53,
these proteins will be particularly important under conditions
that induce/activate p53. p53 is considered a tumour
suppressor protein because of its inhibitory effects on cell
growth. It is found at low levels in most cells under normal
conditions but can be rapidly induced and activated in
response to injury/cellular stresses including ischaemia,
hypoxia, DNA damage and oxidative stress.31–33 When
activated, p53 can give rise to diverse cellular effects including
cell cycle arrest, DNA repair or apoptosis, depending on which
of its target genes are activated. For example, under mild
stress, p53 increases the expression of p21cip1/waf1, asso-
ciated with senescence and differentiation, whereas extensive
damage or severe stress stimulates pro-apoptotic p53 target
genes, for example, Bax, Noxa and PUMA, thereby triggering
apoptosis.33,34 The diverse effects of p53 on cell fate are
highly regulated by its interaction with other cellular proteins,
such as Brn-3a, which blocks p53-mediated apoptosis but co-
operates with p53 to promote senescence/differentiation,29,30
whereas Brn-3b co-operateswith p53 to enhance apoptosis.24
Brn-3b and Brn-3a expression have previously been
reported in cardiomyocytes,35 whereas p53 is undetectable
in healthy adult hearts but has been implicated in different
cardiac pathologies, including hypoxia and ischaemia/reper-
fusion (I/R) injury.36,37 Despite conflicting reports regarding its
role(s) in the heart, p53 is now considered to be important for
mediating the responses in injured cardiomyocytes36–39
because p53 knockout (KO) mice show increased survival
following left coronary artery occlusion.37 Similarly, cardiac-
specific reduction of p53 attenuates apoptosis in the infarct
border zone after coronary artery ligation and reduces
ventricular remodelling during the late phase of MI.39
Furthermore, p53 is induced in response to hypoxia in isolated
cardiomyocytes,36 whereas pro-apoptotic p53 target genes
are implicated in the death of injured cardiomyocytes.40–45
In this study, we demonstrate that Brn-3b and Brn-3a are
increased in the injured heart and co-localise with p53 in
distinct regions in relation to the site of injury. Furthermore,
Brn-3b co-expression with p53 within the infarct zone
correlated with cleaved caspase-3 positivity and increased
pro-apoptotic genes, PUMA, Noxa and Bax. In vitro studies
show that simulated ischaemia/reoxygenation (sI/R) also
induces Brn-3b and p53 in primary cultures of neonatal rat
ventricular cardiomyocytes (NRVM) or rat embryonic-heart-
derived H9c2 cells and this correlates with increased pro-
apoptotic genes and cleaved caspase-3. Finally, short-hairpin
RNA (shRNA)-mediated reduction of Brn-3b protein is
sufficient to attenuate the expression of pro-apoptotic genes
and increase cell survival, even though p53 expression is
unchanged. The implications of these findings in relation to
determining cell fate in the injured heart are discussed.
Results
Brn-3b and Brn-3a TFs are induced in cardiomyocytes
following coronary artery ligation. MI was induced in
mouse hearts by permanent ligation of the left anterior
descending (LAD) coronary artery and changes in tissue
viability were assessed by triphenyltetrazolium chloride
staining (Figure 1a). Quantification of non-viable tissue
showed substantial increase (440%) in cell death by 6 and
24 h after ligation (Figure 1b). To examine the cell death
Figure 1 (a) Triphenyltetrazolium chloride staining showing infarct size (white zone) in sections taken from hearts after sham surgery or at sham, 6 h and 24 h post permanent
LAD ligation surgery. (b) Myocardial infarct size was expressed as a percentage of the left ventricle area (mean± S.E.M. (n= 4/groups)). (c) Representative immunoblots
showing the expression of apoptotic markers, cleaved casapse-8 and caspase-3 and necroptosis markers, RIP1 and RIP3 in sham hearts compared with tissues taken from
hearts at 6 h and 24 h following permanent LAD ligation surgery (n= 3 per group)
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pathways that were activated in the injured heart, we
analysed for changes in apoptotic markers (cleaved
caspase-3 or -8) and necroptosis markers (RIP-1/-3).46,47
Figure 1c shows that cleaved caspase-3 and -8 were
increased by 6 h post ligation and remained elevated at
24 h, thereby confirming that apoptosis occurred during early
time points following permanent coronary artery ligation.4,48
RIP-3 and RIP-1 were only detected at 24 h post MI,
suggesting that necroptosis occurs at later time points.
As Brn-3b and Brn-3a TFs are expressed in cardiomyocytes
and have antagonistic effects on cell survival, we next used
quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) to analyse for changes in mRNA encoding these
TFs in whole hearts following coronary artery ligation,
compared with sham controls. Figure 2a(i) shows that
increased Brn-3b mRNA was observed as early as 1 h after
coronary artery ligation; maximally expressed after 1 day and
reduced by 1 week although levels remained higher than
baseline. In contrast, Brn-3a mRNA was unchanged at 1 h,
increased significantly after 1 day but decreased after 1week.
Cardiomyocyte fate is affected by its location in relation to
the infarct zone; hence, we next analysed protein levels in
tissues isolated from the infarct zone and from uninjured
regions of the heart. Figure 2b(i) shows representative Brn-3a
and Brn-3b expression in non-infarcted and infarcted heart
tissue (Figure 2b(ii)). Brn-3a protein was only detected in non-
infarct regions but not in the infarct zone (Figure 2b), whereas
Brn-3b showed more complex changes. Thus, uninjured (non-
infarct) tissue expressed Brn-3b(l) and Brn-3b(s) isoforms as
well as an intermediate band that was regulated in a similar
manner to Brn-3b(s). In contrast, the infarct zone expressed
increased Brn-3b(l) but reduced Brn-3b(s). Although cleaved
caspase-3 was not detected in the non-infarct myocardium,
significant increases in the infarct area confirmed the
presence of apoptotic cells and suggest that Brn-3b(l) may
be specifically increased in injured myocardium.
To determine cellular localisation in cardiomyocytes, co-
immunostaining was carried out for each protein and α-actinin,
on transverse sections of 1 day post-ligation hearts. Repre-
sentative immunofluorescent images demonstrated that both
TFs co-localised with α-actinin (Figures 2c(i) and (ii)). Brn-3a
was primarily expressed in the non-ischaemic regions of the
heart but not in the infarct zone, whereas Brn-3b was detected
in the non-ischaemic regions of the heart (Figure 2c(i)) (top
panel) and in the infarct zone (bottom panel). Increased
cleaved caspase-3 was detectedwithin the infarct zone but not
in the non-ischaemic areas (Figure 2d(i)), whereas co-staining
with α-actinin confirmed that cardiomyocytes in the infarct
zone were undergoing apoptosis (Figure 2d(ii)).
Co-expression of p53 with Brn-3b or Brn-3a in distinct
regions of injured hearts. As p53 controls genes that affect
cell survival in injured tissue, we next analysed p53 protein
levels in the infarcted or uninjured heart tissues. Figure 3a
shows that p53 protein was undetectable in the uninjured
myocardium but was expressed in the infarct zone. Since
Brn-3a and Brn-3b cause differential effects on cell survival
when co-expressed with p53, co-immunostaining was carried
out on heart sections at 1 day after coronary artery ligation.
Figure 3b shows that p53 protein was expressed around the
infarct zone but was not detected in the non-ischaemic
regions of the heart, so did not overlap with Brn-3a apart from
in a subset of cells adjacent to the infarct zone, which co-
expressed both Brn-3a and p53 (Figure 3b(iii)). In contrast,
Brn-3b co-localized with p53 in cells within the infarct zone
(Figure 3c(ii)) but was also expressed in the non-ischaemic
regions of the heart, which lacked p53 (Figure 3c(i)).
However, this antibody did not distinguish between the
different Brn-3b isoforms.
To test how changes in p53 and Brn-3a or Brn-3b affected
gene expression linked to survival, in injured heart, qRT-PCR
was used to analyse for changes in mRNA encoding target
genes regulated by these factors. Figure 4a shows increased
expression of pro-apoptotic Bax and Noxa and to a lesser
extent PUMA mRNA in hearts at 1 day after LAD artery
ligation, when compared with NS or sham control hearts,
whereas anti-apoptotic, Bcl-2 and Bcl-XL mRNA remained
unchanged. p21cip1/waf1 mRNA was also increased in these
hearts. Fluorescent images of immunostained heart sections
showed strong signals for Bax and Noxa proteins in the infarct
zone of the heart, with weaker staining in the non-infarcted
myocardium, particularly for Noxa (Figure 4b). Although there
were small increases in PUMAmRNA, this protein was readily
detected by immunostaining in the infarct zone but was
undetectable in the non-ischaemic regions or in sham control
heart. Thus, increased Brn-3b and p53 in the infarcted
myocardium correlated with elevated expression of pro-
apoptotic genes.
Simulated ischaemia/hypoxia+reoxygenation increases
Brn-3b, p53 in NRVM cultures. Next, in vitro studies were
carried out in NRVM that express endogenous Brn-3a and
Brn-3b proteins, whereas p53 can be induced by simulated
ischaemia/reoxygenation (sI/R). Methylthiazolyldiphenyl-
tetrazolium bromide (MTT) assays demonstrated reduced
cell viability in NRVM cultures following 4 h simulated
ischaemia/hypoxia (sI), which was sustained after reoxygena-
tion (Figure 5a). However, immunoblotting showed that the
apoptotic marker, cleaved caspase-3, was undetectable
following sI but was expressed after reoxygenation
(Figure 5b), suggesting that apoptotic cell death occurs after
reoxygenation, whereas the loss of viable cells after sI may
be associated with necrotic death.
qRT-PCR showed increased Brn-3b mRNA in NRVM
cultures following sl which continued to rise (≥20-fold),
6–18 h after re-oxygenation (sI/R) (Figure 5c(i)) whereas p53
and Brn-3a mRNA were unchanged after sI but increased after
6 h re-oxygenation (Figure 5c(ii+iii)). Immunoblots demonstrated
that both Brn-3b(l) and Brn-3b(s) protein isoforms were
expressed in control cells (Figures 5e and f) but only the
longer Brn-3b(l) was increased following sI or sI/R whereas
Brn-3b(s) was reduced. On the other hand, p53 protein was
only increased following 6 h sI/R whereas Brn-3a protein
was reduced during sI and at immediately after sI/R but was
increased at 12–18 h.
Interestingly, mRNA encoding pro-apoptotic Bax, Noxa and
PUMA were increased following sI/R, whereas pro-survival
genes, Bcl2 and Bcl-XL, remained unchanged (Figure 5d). To
confirm changes in protein expression, immunoblots were
carried out. Figure 5e shows increased Noxa and PUMA
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proteins following reoxygenation but Bax protein did
not change significantly even though mRNA was higher
(Figures 5d–f).
In view of the opposite effects of Brn-3a and Brn-3b on cell
survival when co-expressed with p53, co-localisation studies
were next carried out in NRVM subjected to sI/R. Figure 5g
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shows that p53 was co-localised with Brn-3a or Brn-3b in
distinct subsets of cells. Interestingly, cells co-expressing
Brn-3b and p53 displayed nuclear division and morphological
changes that suggest cellsmay be undergoingmitotic division.
To test if pro-apoptotic genes were co-expressed with Brn-
3b following sI/R treatment, co-immunostaining was carried
out using α-rabbit Noxa or Bax primary antibodies (green) and,
in this instance, α-goat primary antibody (red) was used to
detect Brn-3b. Representative images (Figure 5i) show that
following sI/R treatment, nuclear expression of Brn-3b protein
was observed in cells that also co-expressed Noxa (i) or Bax
(ii), confirming that Brn-3b is co-localised with these apoptotic
target genes in response to injury.
Reducing Brn-3b attenuates the expression apoptotic
genes in NRVM following sI/R injury. To test whether
Brn-3b was required for maximal expression of pro-apoptotic
genes, as previously shown,24 lentiviral vectors expressing
shRNA to target Brn-3b (3b-sh) or non-silencing control (NS-
sh) were used to infect NRVM cultures which were then
subjected to sI/R (4 h+6 h). As shown in Figure 6, 3b-shRNA
reduced Brn-3b protein levels following sI/R compared with
NS-sh cells. Furthermore, 3b-sh also caused the reduction of
Bax and Noxa proteins when compared with NS-sh control
although p53 expression was relatively unchanged, when
compared with β-tubulin. These results confirm that Brn-3b
was important for maximal expression pro-apoptotic Bax and
Noxa proteins in injured cells.
Brn-3b and p53 expression in H9c2 cells following
simulated ischaemia/hypoxia+reoxygenation. Similar
sI/R studies were carried out in embryonic rat heart-derived
H9c2 myoblasts cells and MTT assays showed that sI for 8h
caused significant loss of cell viability (~60%) (Figure 7a(i)).
Fluorescence activated cell sorting (FACS) analyses demon-
strated increased PI staining after sI, (Figure 7b(i)), confirm-
ing necrosis as the primary form of cell death under these
conditions (Figure 7b(ii)). In contrast, significant increases in
Annexin-V staining at 12 h after sI/R (iii) suggest that more
cells were undergoing apoptosis in response to reoxygena-
tion injury.
qRT-PCR analysis showed increased Brn-3b and p53
mRNA at 12 h after sI/R in H9C2 cells, whereas Brn-3a mRNA
wasmaximally expressed 24 h after sI/R (Figure 7c). Immuno-
blots (Figure 7e) showed that proteins were reduced after sI
and immediately following sI/R (1–6 h). However, Brn-3b and
p53 were increased by 12–24 h after sI/R, whereas Brn-3a
was only increased after 24 h (Figure 7d), suggesting some
differences in responses between NRVM and H9c2 cells.
PUMA protein was increased within 1 h after sI/R, whereas
Noxa was maximally expressed by 8–12 h and Bax was
increased by 24 h suggesting that these proteins may control
cell fate at different times after injury.
Silencing Brn-3b using SH shRNA reduces pro-apoptotic
genes and attenuates apoptosis in H9c2 cells. We next
tested whether targeting Brn-3b affected gene expression
and cell viability in H9c2 cells also by using 3b-sh or NS-sh
lentiviral vectors. Cells were then subjected to sI/R (8 h+12 h)
or left untreated and immunoblots were used to confirm
reduced Brn-3b protein in 3b-shRNA-treated cells. MTT
assays showed that 3b-shRNA significantly increased cell
viability following sI/R when compared with NS-sh control
cells but had no effect in control untreated cells (Figure 8a).
Loss of Brn-3b following sI/R correlated with reduction of pro-
apoptotic Bax and Noxa proteins when compared with NS-sh
(Figure 8b) but had no effect on p53 expression. This
confirms that Brn-3b was important for maximal expression of
these pro-apoptotic proteins in injured cells.
Discussion
Cardiomyocyte death that occurs following coronary artery
occlusion can cause irreversible damage to the heart because
these terminally differentiated cells have poor regenerative
capacity and are not readily replaced. To attenuate such
damage, it is important to understand the complex mechan-
isms that control cell death in the injured heart. In this study, we
have identified Brn-3b and Brn-3a TFs as potential regulators
of cardiomyocyte fate following permanent occlusion of the
LAD coronary artery, which caused significant loss of viable
tissue within 6 h. This model of injury induced apoptotic
markers, caspase-3 and -8 in the heart by 6 h, which was
sustained at 1 day whereas necroptosis markers, RIP-1/3,
were undetectable at 6 h but were induced by 24 h, after injury.
This is in line with previous studies in rat hearts in which
permanent coronary artery ligation caused apoptotic cell
death by 2–4 h after injury but with the peak of necrotic cell
death detected at later times (24 h).9,46 Under these condi-
tions, Brn-3b mRNAwas increased as early as 1 h after injury,
Figure 2 (a) qRT-PCR data showing changes in mRNA encoding Brn-3b (i) and Brn-3a (ii) in hearts following ligation of the LAD after 1 h (H 1), 1 day (D 1) and 1 week (W1),
compared with control hearts taken from mice with either no surgical intervention (NS) or sham surgery (sham). Relative mRNA levels were normalised to the housekeeping gene,
GAPDH, (to adjust for variations between different samples) and fold changes, calculated usingΔΔCT method, were expressed relative to sham control (set at 1). Values shown
represent the mean± S.D. of45 independent hearts at each time point. Statistical significance was assessed by Student’s t-test. *Po0.05, **Po0.01, ***Po0.001. (b) (i)
Representative immunoblots showing Brn-3b and Brn-3a proteins in tissues taken from non-infarct area and infarct zone of hearts following coronary artery ligation. Each lane
represents proteins expressed in a different heart. The longer Brn-3b isoform is shown as Brn-3b(l) and Brn-3b(s) represent the shorter protein. * shows the position of an
additional band that is slightly larger than Brn-3b(s) and is regulated in a similar manner. Cleaved caspase-3 was used to determine apoptotic changes in these regions of the
heart, whereas GAPDH levels were used to show variability in protein levels. (ii) Bar graph showing quantification of Brn-3b and Brn-3a protein expression in non-infarct
tissue compared with the infarct zone, using densitometry of immunoblots, which were normalised to GAPDH levels for each sample (mean± S.E.M. of 45 independent
samples). (c) Representative immunofluorescence images of transverse sections of mouse hearts harvested at 1 day after ligation showing Brn-3b or Brn-3a (green), co-stained
with sarcomeric α-actinin (red), as a marker of cardiomyocytes. Non-infarcted images refer to tissues in uninjured region of the heart, whereas the infarct zone represents tissues
around the site of injury. Merged images show the overlay of Brn-3b or Brn-3a with α-actinin as well as DAPI staining, which identify the nuclei of cardiomyocytes in these sections.
Images were captured at × 25 magnification. (d) (i) Immunofluorescent images showing cleaved caspase-3 protein expression in the infarct zone but not in the non-infarcted tissue
in hearts at 1 day after coronary artery ligation. DAPI staining indicates the location of cell nuclei within this section. (ii) Images ( ´ 100) showing co-staining of activated casp-3
(green) with α-actinin (red) in cardiomyocytes within the infarct zone of hearts, 1 day after LAD ligation. DAPI staining (blue) indicates the cell nuclei in the sections
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continued to increase at 1 day and although reduced after
1 week, levels remained significantly higher than baseline. On
the other hand, Brn-3a mRNA was only increased after 1 day
but was reduced by 1 week. Furthermore, analysis of protein
expression confirmed these changes but identified distinct
expression patterns in relation to the site of injury. Thus, Brn-
3a protein was only detected in cardiomyocytes isolated from
the non-infarcted regions of the heart but not at the site of
injury, and localisation studies showed restricted expression to
non-injured regions of the heart. On the other hand, Brn-3b
showed more complex, isoform-specific regulation because
uninjuredmyocardium expressed both Brn-3b(l) andBrn-3b(s)
isoforms and an additional protein band, slightly larger than
Brn-3b(s), that was not expressed in the infarct zone. Although
still to be characterised, this may represent some posttransla-
tional modification of the Brn-3b(s) protein expressed in the
heart in response to the injury model used. In contrast, only
Brn-3b(l) was increased in the injured myocardium, whereas
the shorter Brn-3b(s) protein was downregulated. Immuno-
staining showed Brn-3b expression throughout the injured
heart but the antibodies used for these studies recognised
both isoforms. As such, the potential distribution of Brn-3b(l)
and(s) proteins and implications of their differential expression
in the injured heart are still to be determined.
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Figure 3 (a) Representative immunoblots showing p53 protein levels in tissues taken from uninjured (non-infarct) tissue or infarct zone, whereas GAPDH expression was
consistent across samples. (ii) Graph showing changes in p53 protein in the infarct zone, compared with non-infarct tissue. Proteins have been normalised to GAPDH levels and
represent mean±S.E.M. of45 samples. (b and c) Representative immunofluorescence images of heart sections showing co-staining for p53 (red) and either Brn-3a (green) (b)
or Brn-3b (c) in the infarct zone (i) or non-infarcted regions (ii), whereas co-staining in myocytes adjacent to the infarct zone was only shown for Brn-3a and p53 (iii). Merged
images show the overlay of either Brn-3a or Brn-3b with p53, whereas DAPI identifies the nuclei of cardiomyocytes in these sections
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p53 was also induced in this model of cardiac injury but
expression was restricted to the infarct zone and the border
zone, adjacent to the site of injury. Interestingly, Brn-3a and
p53 proteins were mutually exclusive in the injured heart apart
from a subset of myocardium adjacent to the infarct zone
where these proteins were co-localised. On the other hand,
Brn-3b protein, which was detected throughout the injured
heart, was co-localised with p53 in myocardium within the
infarct zone. Despite conflicting reports regarding its role in
cardiomyocyte apoptosis, increasing evidence now supports
p53 as a regulator of cell fate in the injured heart because p53
KO mice showed increased survival following coronary artery
occlusion, with reduced LV wall thinning and LV rupture
compared with wild-type controls.37 Similarly, cardiac-specific
reduction of p53 using an endogenous p53 antagonist, CHIP,
also reduced apoptosis around the infarct border zone after
coronary artery ligation and caused less ventricular remodel-
ling during the late phase of MI.39 These findings clearly linked
p53 expression with increased apoptosis and, interestingly,
elevated Brn-3b and p53 in the injured hearts at 1 day after
coronary artery ligation correlated with increased apoptotic
marker, cleaved caspase-3 and maximal expression of
pro-apoptotic proteins, Bax, Noxa and PUMA although anti-
apoptotic Bcl-2 and Bcl-XL remained relatively unchanged.
Bax and PUMA proteins were highly expressed in the infarct
zone whereas Noxa was detected at the site of injury but also
found at lower levels in the non-ischaemic myocardium,
suggesting potential contribution to apoptosis at different sites
in the heart. These pro-apoptotic proteins have been
implicated in cell death following ischaemic/hypoxic injury,
with Bax KO mice showing reduced infarct size and less
ventricular remodelling after prolonged ischaemia,
whereas Langendorf-perfused Bax KO hearts exhibit reduced
caspase-3 activity and improved cardiac function after I/R
injury.49,50 PUMA is also implicated in cardiomyocyte apopto-
sis following I/R-induced injury and heart failure and targeted
deletion of PUMA in mice has been associated with reduced
infarct size because of decreased apoptosis and necrosis.43,51
Although Noxa has not been extensively studied in the heart,
its expression is linked to apoptosis in response to
hypoxia,52–54 and in this study, we have seen significant
increases in Noxa protein following coronary artery ligation in
the heart. As Brn-3b co-operates with p53 to enhance
apoptotic genes and cell death, it is likely to control myocyte
fate in the injured myocardium if co-expressed with p53.
The requirement for Brn-3b in controlling the expression of
these pro-apoptotic proteins was supported by studies carried
out using in vitro cell culture models subjected to sI or sI/R. In
line with previous reports, p53 expression was induced in
NRVM cultures following sI/R,7,36 whereas Brn-3b was
increased in response to sI and continued to increase
following sI/R. Importantly, maximal expression of Brn-3b
Figure 4 (a) qRT-PCR data showing changes in mRNA that encode different target genes including Bax (i); Noxa (ii); Puma (iii); p21cip1/waf1 (iv); Bcl-2 (v) and (vi) Bcl-xL in
injured mouse heart following coronary artery ligation for 1 h or 1 day, compared with NS or sham control hearts. mRNA levels were normalised to GAPDH mRNA and fold
changes expressed relative to the NS control heart (set at 1). Values shown represent mean± S.D. from45 independent hearts at each time point with statistical significance
assessed using Student’s t-test (*Po0.05, **Po0.01, ***Po0.001). (b) Immunofluorescence images of heart sections (1 day after coronary artery ligation) stained with
antibodies to recognise (i) Bax (ii) Noxa or (iii) PUMA proteins. Representative images of staining in the infarct zone or non-infarct zone in ligated hearts compared with sham
control hearts. DAPI staining was used to show location of nuclei in the sections
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and p53 after 12 h of sI/R correlated with increased Noxa and
PUMA expression although with only minimal changes in Bax
mRNA. However, relatively high levels of pro-apoptotic genes
were observed at baseline in NRVMs, which may reflect
stresses sustained by the cells when grown in culture. Despite
this, increased Noxa and PUMA may be important for
increased apoptosis seen in isolated cardiomyocytes, 12 h
after sI/R. Similar studies in H9c2 cells confirmed the
relationship between increased Brn-3b and p53 with
maximal expression of pro-apoptotic genes, Bax, Noxa and
PUMA and confirmed the suitability of this model for analysing
the interactions between Brn-3b or Brn-3a and p53, in relation
to cells fate determination. Furthermore, targeting Brn-3b
using shRNA in NRVM or H9c2 cells was sufficient to reduce
Bax and Noxa protein levels, even though p53 remains
unchanged. Furthermore, Brn-3b shRNA also attenuated
a
b
c
d
Figure 5 (Continued)
Brn-3b and p53 in injured cardiomyocytes
V Budhram-Mahadeo et al
8
Cell Death and Disease
e f
g h
Figure 5 (Continued)
Brn-3b and p53 in injured cardiomyocytes
V Budhram-Mahadeo et al
9
Cell Death and Disease
death in H9c2 cells following sI/R, compared with treated cells
infected with non-silencing controls. Therefore, Brn-3b is
required for maximal expression of pro-apoptotic genes
following stresses such as sI/R that stimulate apoptosis.
This is in line with previous observations showing that Brn-3b
was essential for maximal induction of Bax in neurons
because primary cultures from Brn-3b KO mice were highly
resistant to apoptotic stimuli which caused significant death in
control neurons and expressed reduced Bax mRNA even
though p53 expression remain intact.24 Thus, Brn-3b may
be a crucial regulator of apoptotic cell death in injured
cardiomyocytes.
Interestingly, Brn-3b was increased earlier than Brn-3a or
p53 in-vivo (by 1 h following coronary artery ligation) and
in-vitro (after sI). This suggests distinct functions for Brn-3b
proteins in cardiomyocytes at different times following injury,
depending on p53 levels but potential cardiac-specific Brn-3b
target genes are still to be identified. Interestingly, this TF can
drive cell cycle progression by activating transcription of cell
cycle proteins such as cyclin D1 and some cardiomyocytes
that co-express Brn-3b and p53 demonstrate morphological
characteristics of active mitotic division within the nuclei.
Terminally differentiated cells such as cardiomyocytes are
thought to respond to injury by abortive attempts to re-enter
the cell cycle.55–57 This often precedes cell death referred to
as mitotic catastrophe, which is considered as a distinct cell
death pathway that results from aberrant control of the cell
cycle.58 p53 and its target genes, Bax and PUMA, have
been implicated in driving mitotic catastrophe.58,59 However, if
Brn-3b can affect their expression under these conditions,
this may be important for cell fate determination. In this regard,
it is possible that early Brn-3b increases in injured cardiomyo-
cytesmay stimulate distinct targets, including cell cycle genes,
involved in initial responses to injury. However, if the growth-
suppressing p53 is induced in Brn-3b-expressing cells, then
conflicting signals arise, which cause the cell cycle to be
aborted and under these conditions, Brn-3b co-operates with
p53 to increase transcription of pro-apoptotic genes, thereby
precipitating cell death. Potential roles for Brn-3b in regulating
pro-apoptotic genes during mitotic catastrophe may provide a
novel method for controlling cell fate. As reducing Brn-3b is
sufficient to increase cell viability and reduce pro-apoptotic
proteins such as Bax, even though p53 expression is
unchanged, these findings confirm that Brn-3b is required for
maximal expression of pro-apoptotic target genes in injured
myocardium and therefore likely to be very important for
mediating such cell fate decisions following MI.
The effects of increased Brn-3a in cardiomyocytes within
the non-infarcted regions of the heart are still to be elucidated
because Brn-3a target genes, Bcl-2 and Bcl-XL, were not
increased in whole hearts but maybe locally increased in
surviving cardiomyocytes. However, because Brn-3a can also
block p53-mediated apoptosis, it may enhance other p53
target genes, such as NOS3, which is associated with survival
in oxygenated myocardium outside the infarct zone.60 In this
regard, although Brn-3a inhibits p53-mediated apoptic genes,
it may cooperate with p53 to regulate distinct target genes that
promote survival of specific cell populations that might affect
long-term outcome in the injured heart.
Thus, these results provide evidence to support Brn-3b and
potentially Brn-3a as key regulators of p53-mediated effects in
the heart following injury. The high homology between Brn-3b
and Brn-3a in the DNA-binding POU domain (495%), which
also mediates the interaction with p53, suggests that
competition between these TFs either for interaction with
p53 or binding to promoters of target genes can affect outcome
Figure 5 (a) MTTassay showing changes in percentage of viable cells in NRVM cultures subjected to simulated ischaemia/hypoxia (I) followed by reoxygenation for different
times. Values are expressed as percentage decrease of viable cells compared with untreated control cells (set at 100%). Statistical significance was obtained using Student’s
t-test with *Po0.05, **Po0.01. (b) (i) Representative immunoblot showing cleaved caspase-3 protein levels in NRVM cultures subjected to 4 h ischaemia/hypoxia alone or with
reoxygenation at specified times. (ii) Bar graph showing changes in cleaved caspase-3 protein expression in different samples following densitometry of immunoblots, normalised
to GAPDH levels for each sample (mean± S.E.M. of45 independent samples). (c) qRT-PCR data showing changes in mRNA encoding Brn-3b (i), p53 (ii) and Brn-3a TFs, in
NRVM cultures, treated as indicated. Gene expression was normalised to GAPDH mRNA and expressed as fold changes compared with untreated control (set at 1). Values
represent mean± S.E.M. of43 independent experiments at each time point and Student’s t-test shows significance, *Po0.05, **Po0.01, ***Po0.001. (d) qRT-PCR analysis
showing changes in mRNA encoding Bax (i), Noxa (ii), Puma (iii), p21cip1/waf1 (iv), Bcl-2 (v) and (vi) Bcl-xL in NRVM cultures following ischaemia/hypoxia − /+ reoxygenation for
different periods. mRNA levels were normalised to GAPDH mRNA and fold changes calculated using ΔΔCT method. Values are expressed as fold change relative to the
untreated control cells (set at 1). Values represent mean± S.D. from 43 independent hearts at each time point with statistical significance assessed using Student’s t-test
(*Po0.05, **Po0.01, ***Po0.001). (e) Representative immunoblots showing changes in protein expression in NRVM cultures under different conditions. C= untreated control;
Isc= 4 h ischaemia/hypoxia; Isc+R= 4 h ischaemia followed by reoxygenation for the time indicated. (f) Quantification of protein expression by densitometry and normalisation to
GAPDH levels. Data are expressed as mean±S.E.M. fold change vs untreated cells of43 independent experiments. (g) Representative immunofluorescent images (×25)
showing expression of p53 (top panel-red) or Brn-3a (middle panel-green) in NRVMs treated with 4 h ischaemia+12 h reoxygenation. Merged images (lower panel) show
co-localisation of p53 and Brn-3a, whereas DAPI identified the cell nuclei. * indicates specific cells that co-express Brn-3a and p53, whereas arrows show the cells that express
Brn-3b but not p53. (h) Co-localisation of p53 (red) or Brn-3b (green) in NRVMs following ischaemia (4 h) and reoxygenation (12 h) at × 25 magnification. Merged images
(right panel) show co-localisation of p53, Brn-3b and DAPI with * indicating cells that co-express Brn-3b and p53. Lower panels show higher magnification (×100) of a
representative cell that co-expresses Brn-3b and p53 and show evidence of nuclear division (seen by DAPI stain). (i) Representative images showing Brn-3b (red) co-localised in
cells that express either Noxa (green-top panels) or Bax (bottom panels) after ischaemia/reoxygenation
Figure 6 Immunoblot to show changes in Brn-3b, Noxa and Bax proteins in
3b-sh-RNA-infected cells compared with NS controls. p53 protein is also shown whereas
β-tubulin is used to indicate differences in protein loading between different samples
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on cell fate. As such, the data showing distinct localisation and
co-expression of Brn-3b or Brn-3a with p53 in relation to the
injury site is also important for understanding how these
factors may control target gene expression and hence the fate
of cardiomyocytes, following injury. This is important for
elucidating the mechanisms through which these regulators
control the fate of cardiomyocytes following injury and will be
vital for identifying strategies for increasing cell survival and/or
reducing cell death following ischaemic/hypoxic insults that
occur in MI.
Materials and Methods
Materials. General laboratory reagents were purchased from Merck (Notting-
ham, UK) and Sigma (Dorset, UK) unless otherwise stated. All tissue culture
reagents were supplied by Gibco/Life Technologies (Paisley, UK). Tissue culture
plasticware was obtained from Nunc (Paisley, UK) and other general disposable
plasticware was from Greiner (Stonehouse, Gloucester, UK) and Corning (supplied
by Scientific Laboratory Supplies, Nottingham, UK). Reagents for immunohisto-
chemistry were obtained from Vector Laboratories (Peterborough, UK) and
Invitrogen/Life Technologies (Paisley, UK). Primary antibodies were sourced as
follows: α-Brn-3b (rabbit pAb), α-PUMA-(rabbit pAb) and α-Noxa (rabbit pAb)
(Abcam, Cambridge, UK); α-Brn-3b-(goat pAb), GAPDH, (rabbit pAb) and α-actin
(goat pAb I-19) (Santa Cruz Biotechnology Inc, Dallas, TX, USA); α-Brn-3a (rabbit
pAb) (Millipore, Dundee, UK), α-p53 (sheep pAb) or (mouse mAb) (Calbiochem,
Millipore, Billerica, MA, USA), α-Bax, (rabbit pAb) and α-Cleaved caspase-3,
(Rabbit pAb) (Cell Signalling, Danvers, MA, USA), α-actinin Mouse (Sigma),
α-RIP-1 antibody (Cell Signalling 3493), RIP-3 (ab56164), cleaved caspase-8 (CS
4790) and HRP-conjugated secondary Ab from Dako (Cambridgeshire, UK).
Lentiviral vector, pGIPZ Brn-3b shRNA (si3B) used to target Brn-3b and control
a b
Figure 7 (a) Results of MTTassays showing percentage of viable cells in H9c2 cultures subjected to 8 h simulated ischaemia/hypoxia (I) followed by reoxygenation (R) for
different times. Values are expressed as percentage decrease compared with untreated control cells (set at 100%) and significant changes are indicated (***Po0.01).
(b) (i) Representative FACS plots showing the different populations. H9c2 cells that are stained with PI as a marker of necrotic cell death (y axis) or annexin V for apoptotic cells
(x axis) at different times following sI or sI/R. Graphical representation of PI-positive cells undergoing necrosis is shown in (ii), whereas changes in apoptosis, as represented by
Annexin V-positive cells are shown in (iii). Significance is indicated by *Po0.05, **Po0.01, ***Po0.001. (c) qRT-PCR analysis showing changes in mRNA encoding Brn-3b,
p53 or Brn-3a in H9c2 cells treated with ischaemia/hypoxia without or with reoxygenation for different periods. mRNA levels were normalised to GAPDH and differences
expressed as fold change relative to the untreated control cells (set at 1). Values represent mean± S.D. from43 independent experiments at each time point and significant
changes are indicated by *Po0.05, **Po0.01, ***Po0.001. (d) Representative immunoblots showing changes in Brn-3b, p53 or Brn-3a proteins in untreated and treated H9c2
cells relative to invariant GAPDH protein. (e) qRT-PCR analysis of mRNA encoding Puma, Noxa, Bax or p21cip1/waf1 in H9c2 cells treated as indicated. mRNA levels were
normalised to GAPDH and values expressed as fold change relative to the untreated control cells (set at 1). Mean± S.D. from43 independent experiments were used to
determine statistical significance using Student’s t-test (*Po0.05, **Po0.01, ***Po0.001)
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non-silencing (NS) shRNA were obtained from Open Biosystems, Thermo Scientific
(Pittsburgh, PA, USA) via UCL Genomics.
In vivo coronary artery ligation. All animal experiments complied with
Home Office regulations as detailed in the Guidance on the Operation of the
Animals (Scientific Procedures) 1986 and were reviewed and approved by the local
Ethics Review Board. Permanent coronary ligation was carried out using 7–14-week
old C57BL/6NTac mice as previously described.61,62 Briefly, anaesthetised mice
were ventilated by orotracheal intubation prior to performing left thoracotomy to
expose the LAD coronary artery which is ligated (using 8-0 nylon suture) in
experimental animals or left unligated in sham controls and mice were allowed to
recover. Physiological measurements were taken at baseline, after 1 day or 1 week
using a Vevo 770 ultrasound imaging system (Fuji film Visual Sonics, Toronto, ON,
Canada). At the end of experiments, hearts were excised, rinsed with saline and
prepared for subsequent analysis. Western blot analyses were carried out using
protein samples obtain from the border zone and the infarct area. For molecular
analysis, excised hearts were snap-frozen in liquid nitrogen and stored at − 80 °C
until use. In some cases, hearts were divided into the infarct from the non-infarct
area prior to freezing. Histological assessment of sites of injury in the hearts (e.g.,
haematoxylin and eosin staining) was carried out using 8-μm sections of hearts that
were embedded in OCT compound (Raymond Lamb).
Triphenyltetrazolium chloride staining. At 6 or 24 h post MI, mice were
killed and the heart was quickly excised, sliced into four 1.0-mm-thick sections
perpendicular to the long axis of the heart. The sections were then incubated with
1% triphenyltetrazolium chloride at 37 °C for 10 min and then scanned. The infarct
area was measured using ImageJ software and myocardial infarct sizes were
expressed as a percentage of the left ventricle area.
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Figure 8 (a) Results of MTT assays showing changes in viability of H9c2 cells
infected with shRNA to target Brn-3b (3bsh) and subjected to sI/R. Values are
expressed as fold change compared with non-silencing shRNA (NSsh), which is set
at 1. (b) Immunoblot to show changes in Brn-3b and Bax proteins in 3b-sh infected
cells compared with NS controls. p53 protein is also shown, whereas b-tubulin is used
to indicate differences in protein loading between different samples
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Co-immunostaining for protein expression. Protein localisation was
analysed on frozen heart sections or NRVM cultured on coverslips. Heart sections
were fixed in pre-chilled acetone (5 min) and air-dried at (RT; 5–10 min), followed by
permeabilisation in PBS+0.5% Triton-X100 (PBST) for 5 min. For NRVM cells grown
on coverslips, treated cells or untreated controls were fixed (4% PFA; 15 mins);
washed in 1 × TBS, blocked in PBST+10% goat serum/0.1% w/v BSA for 1 h (RT)
followed by incubation with primary antibody (either 4 °C or 1–2 h at RT). After five
washes in PBST, Alexa Fluor-conjugated secondary antibodies were incubated
for 1 h at RT, followed by 5 × final washes, mounting with DAPI medium
(Vector Laboratories). Fluorescence was visualised using Zeiss (Birmingham, UK)
Axioscop 2 fluorescent microscope and images captured using Axiovision software
(Zeiss).
Cell models. Primary NRVM cultures were prepared from hearts of 1–2-day-old
Sprague-Dawley rats as described.63 Briefly, isolated neonatal hearts, minced in
ice-cold ADS buffer (116 mM NaCl, 20 mM HEPES, 0.8 mM NaH2PO4, 5.6 mM
glucose, 5.4 mM KCl, and 0.6 mM MgSO4) pH 7.35, serially digested in collagenase
type 2 (0.5 mg/ml; Worthington Biochemical Corp, Lakewood Township, NJ, USA)
and pancreatin (0.6 mg/ml; Sigma), centrifuged, then resuspended in 4 : 1
Dulbecco’s Modified Eagle’s Medium/Medium 199 (Gibco, Invitrogen Corporation,
Auckland, New Zealand) supplemented with 10% horse serum and 5% foetal calf
serum +1% penicillin/streptomycin. After 1 h pre-plating (to remove fibroblasts), cells
were plated onto gelatine-coated 6-well plates (2 × 106 cells/well) and cultured for
24 h after which medium was replaced with Dulbecco’s Modified Eagle’s Medium/
Medium 199 (4 : 1)+1% foetal calf serum.
H9c2 cells were maintained in Dulbecco’s Modified Eagle’s Medium with 10%
foetal calf serum and 1% penicillin/streptomycin. For experiments, cells were plated
onto 6-well plates (5 × 105/well).
Simulated Ischaemia/Reoxygenation in cell cultures. To simulate
ischaemia and reperfusion injury in vitro, the culture medium was replaced with
ischaemia buffer (137 mM NaCl, 12 mM KCl, 0.49 mM MgCl2, 0.9 mM CaCl2, 4 mM
HEPES, 20 mM sodium lactate, 10 mM 2-Deoxy-glucose, pH 6.2) as previously
described64 and the cells were incubated in a 37 °C hypoxia chamber with 95%
argon, 5% CO2 for 4 h (NRVM) or 8 h (H9c2 myoblasts). Following ischaemia/
hypoxia, the buffer was replaced with full growth media and the cells were re-
oxygenated by transferring into a tissue culture incubator under normal growth
conditions (5% CO2 at 37 °C), for the indicated times. Control cells were maintained
in normal growth media in incubator.
Gene silencing using ShRNA. To reduce gene expression in H9c2 cells,
lentiviral pGIPZ vectors containing short hairpin RNA sequences (shRNA) were
used to treat cells for 24 h before treatment with sI/R. The shRNA used were
previously shown to effectively reduce Brn-3b (si3B) or Brn-3a (si3a), whereas non-
silencing (NS) control shRNA contained a scrambled sequence. shRNA were used
at 1.5 × 106 PFU (MOI= 0.5) to infect cells prior to treatment.
RNA extraction, cDNA synthesis and qRT-PCR. Total RNA was
isolated from whole hearts, NRVM or H9c2 cells using TRIZOL Reagent
(Invitrogen). Snap-frozen whole hearts were homogenised in liquid nitrogen before
resuspending in Trizol whereas NRVM and H9c2 cells were harvested in Trizol and
processed according to the manufacturer’s protocol. DNAse1 treatment was
performed using RNAse-free DNAse 1 (Promega, Southampton, UK). cDNA
synthesis (20–50 μl reaction) was carried out using RNA Superscript II Reverse
Transcriptase (Invitrogen). Real-time qRT-PCR was carried out using 1–2 μl of
cDNA. ABI Taqman probes or unique primers (for SYBR Green) were used to
quantify each gene and reactions were performed using the Opticon 2 DNA engine
thermal cycler (Bio-Rad, Hemel Hempstead, UK). Beta-2 microglobulin or GAPDH
housekeeping genes were used to correct for variability between samples. Relative
mRNA levels were normalised to GAPDH mRNA and calculated using ΔΔCT
method. Mean± S.D. of 45 independent experiments were used for statistical
analysis using appropriate packages including Student’s t-test or Mann-Whitney
U-test and significance was shown when Po0.05.
Protein preparation and quantification. Cells were harvested in
Laemmli buffer; mouse hearts were pulverised in liquid nitrogen then resuspended
in Laemmli buffer. β-mercaptoethanol (10% (v/v)) was added to samples prior to
boiling (100 °C, 5 min) then centrifuged (13 × g, 10 min RT) to remove cellular
debris. Total cellular proteins were resolved by polyacrylamide gel electrophoresis
(SDS-PAGE) gels (12.5/15%) and immuno blot analysis carried out as previously
described.29 Briefly, block buffer, PBS-T (phosphate-buffered saline+0.1% Tween-
20; 4% milk) was incubated for 1 h; primary Ab (diluted in PBS-T) was incubated for
1 h (RT) or overnight (4 °C) depending on the antibody. After five washes (5 min;
RT; PBS-T +0.1% milk), the second Ab was incubated for 1 h and after final washes
(4 × 5 min; RT; PBS-T +0.1% milk and 1 × 5 min; PBS-T), signals were developed
using enhanced chemiluminescence reagent (Amersham, Bucks, UK). Immunoblots
were quantified by analysing bands using densitometry or Image J.
Cell viability (MTT) assays. Cell viability/proliferation assays were
performed using MTT assays, which relies on the ability of live cells to convert
the yellow tetrazolium salt (MTT (Sigma) to dark blue, water-insoluble MTT
formazan crystals. The conversion in different cultures was detected using
colorimetric measurement and the changes in cell viability shown as percentage of
control untreated cells. To measure cell death in NRVMs and H9c2 cells after sI/R,
monolayer culture of treated cells and untreated controls were rinsed twice with 1 ×
PBS and 500 μl of MTT solution (0.5 mg/ml in 1 × PBS) was added to each well.
After 2 h of incubation at 37 °C, MTT solution was aspirated and 200 μl of DMSO
was added to each well. The plates were incubated for 5 min at room temperature
with gentle rocking to dissolve the formazan crystals. Fifty microlitres of cell
suspension was transferred to the wells of a flat-bottom 96-well plate
and the absorbance was measured at 560 nm using a plate reader (TECAN,
Reading, UK).
Flow cytometry. FACS analysis was carried out to assess the fate of H9c2
cells following sI/R because dual-staining protocol with FITC Annexin V and
propidium iodide (PI) (BD Pharmingen, Oxford, UK) helped to distinguish cells in
early apoptosis (Annexin V positive) or necrosis (PI staining upon loss of membrane
integrity). For these studies, cells were seeded as a monolayer in 6-well plates and
grown O/N prior to the specified treatment. At the end of experiment, cells were
rinsed twice with 1 × HBSS and trypsinised to detached from the wells. Fresh
growth medium was added to the cells prior to centrifugation (1000 × g; 5 min) and
the pellet was resuspended in 100–300 μl of 1 × binding buffer. One hundred
microlitres of the cell suspension was transferred to fresh 1.5 ml eppendorf tubes
and 5 μl of FITC-conjugated Annexin V and/or 5 μl PI were added to cells and
incubated for 30 min at room temperature, mixing gently every 10 min. One millilitre
of FACS buffer (0.5% w/v BSA and 0.1% sodium azide in 1 × PBS) was then added
to each tube and the cell suspensions were centrifuged at 1000 × g for 5 min. To
remove residual Annexin V and PI in the tubes, a washing step was carried out by
dissolving the pellets in 1 ml of FACS buffer, followed by centrifugation at 1000 × g
for 5 min. The pellet was then resuspended in 350 μl of FACS buffer and the entire
cell suspension was transferred to FACS tubes. Analysis was performed using the
FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK). Data were analysed
using the FlowJo data analysis software package (TreeStar, Ashland, OR, USA).
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